Evolving role of leukotrienes in the pathogenesis of viral infections, including otitis media.
Otitis media (OM) is one of the most common childhood disorders and has been associated with an alarming rise in prevalence. Because medical therapy with antibiotics, antihistamines, decongestants, and corticosteroids has no demonstrable efficacy in the treatment of OM, the mainstay of treatment is surgical intervention. Although effective, surgical treatment is quite expensive and exposes patients to the risks associated with general anesthesia. Results of recent studies suggest that locally produced leukotrienes may play a role in the pathogenesis of OM. As such, a potential candidate for treatment of OM is the leukotriene receptor antagonist, montelukast, which has been approved by the US Food and Drug Administration for the treatment of asthma and/or allergic rhinitis. If proven effective, this drug's safety/convenience profiles and indication for children as young as 6 months of age would make it suitable for treatment of OM, and perhaps even prophylaxis of OM in at-risk populations.
Gentile
Deborah
D
Division of Allergy, Asthma and Immunology, Allegheny General Hospital, 320 E North Avenue, Pittsburgh, PA 15212, USA. dgentile@wpahs.org
D000085:Acetates / Q000627:therapeutic use*; D003521:Cyclopropanes; D006801:Humans; D007223:Infant; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D015289:Leukotrienes / Q000378:metabolism; D010033:Otitis Media / Q000453:epidemiology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D011804:Quinolines / Q000627:therapeutic use*; D013440:Sulfides; D014777:Virus Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism / Q000473:pathology
D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D011804:Quinolines; D013440:Sulfides; C093875:montelukast